ClinicalTrials.gg
Active, not recruitingNCT06253221Updated Dec 19, 2025

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Phase 3 interventional study of Mavacamten and Placebo in Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb. Active, not recruiting at 47 sites in 9 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
17th of 21
44 · median 75
Started
2024
with 1 other
Phase 3
6 of 21
none open now
Registered
16th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 17th largest by enrollment, is one of 2 that started in 2024, is one of 6 in phase 3, and was the 16th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

03

Conditions studied

  • Cardiomyopathy, Hypertrophic

Keywords

  • HCM
  • mavacamten
  • Obstructive Hypertrophic Cardiomyopathy
  • SCOUT
  • SCOUT-HCM
  • Pediatric HCM
  • Pediatric hypertrophic cardiomyopathy
  • Symptomatic HCM
  • oHCM
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HCM
  • Presence of LVOT obstruction
  • Presence of symptoms

Exclusion criteria

Exclusion Criteria:

  • Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction
  • Evidence of \<50% in prior 6 months
  • Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)

Other protocol-defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Mavacamten

    Participants assigned to this arm will receive mavacamten (1 mg to 15 mg) from day 1 to end of treatment at week 200.

    Drug: Mavacamten

  • Experimental
    Placebo

    Participants assigned to this arm will receive mavacamten (1 mg to 15 mg) from week 28 to end of treatment at week 200.

    Drug: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986427

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient

    Time frame: At Week 28

Secondary outcomes

  1. Change from baseline in resting LVOT gradient

    Time frame: At Week 28

  2. Change from baseline in post-exercise peak LVOT gradient

    Time frame: At Week 28

  3. Change from baseline in maximal wall thickness

    Time frame: At Week 28

  4. Change from baseline in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e')

    Time frame: At Week 28

  5. Proportion of participants achieving an increase from baseline to Week 28 in peak oxygen uptake test (pVO2)

    Time frame: From baseline up to Week 28

  6. Proportion of participants achieving a reduction from baseline to Week 28 in maximal LVOT gradient to < 30 mmHg

    Time frame: From baseline up to Week 28

  7. Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) class from baseline to Week 28

    Time frame: From baseline up to Week 28

  8. Proportion of participants with at least 1 grade improvement in mitral regurgitation at Week 28

    Time frame: From baseline up to Week 28

  9. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to Week 218

  10. Number of participants with treatment-emergent serious adverse events (TESAEs)

    Time frame: Up to Week 218

  11. Change from baseline in electrocardiogram (ECG) (QT interval)

    Time frame: At Week 28

  12. Number of participants with left ventricular ejection fraction (LVEF) ≤ 30%

    Time frame: Up to Week 200

  13. Number of participants with LVEF < 50%

    Time frame: Up to Week 200

  14. Trough observed plasma concentration (Ctrough)

    Time frame: Up to Week 200

  15. Post-dose plasma concentration of mavacamten

    Time frame: Up to Week 200

  16. Maximum observed concentration (Cmax)

    Time frame: Up to Week 200

  17. Area under the concentration-time curve (AUC)

    Time frame: Up to Week 200

  18. Proportion of participants who evaluate taste and swallowability as neutral or better using taste and swallowability scales

    Time frame: At Day 1 and Week 11

  19. Change from baseline in the Hypertrophic Cardiomyopathy Symptom Questionnaire - Shortness of Breath (HCMSQ SoB) domain

    Time frame: At Week 28

07

Study locations

47 sites
  • Local Institution - 0017
    Birmingham, Alabama 35294-0004, United States
  • Local Institution - 0050
    Phoenix, Arizona 85016-7710, United States
  • Local Institution - 0032
    Los Angeles, California 90027-6062, United States
  • Local Institution - 0008
    Los Angeles, California 90095-8344, United States
  • Local Institution - 0033
    Palo Alto, California 94304-1601, United States
  • Local Institution - 0044
    San Diego, California 92123-4223, United States
  • Local Institution - 0038
    Aurora, Colorado 80045-7106, United States
  • Local Institution - 0031
    St. Petersburg, Florida 33701-4634, United States
  • Local Institution - 0053
    Atlanta, Georgia 30329-3117, United States
  • Local Institution - 0013
    Chicago, Illinois 60637-1447, United States
  • Local Institution - 0009
    Indianapolis, Indiana 46202-5272, United States
  • Local Institution - 0043
    Boston, Massachusetts 02115-5724, United States
  • Local Institution - 0002
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0037
    St Louis, Missouri 63110, United States
  • Local Institution - 0052
    Morristown, New Jersey 07960, United States
  • Local Institution - 0010
    New Hyde Park, New York 11042, United States
  • Local Institution - 0024
    New York, New York 10029-6574, United States
  • Local Institution - 0036
    New York, New York 10032-1559, United States
  • Local Institution - 0040
    The Bronx, New York 10467-2403, United States
  • Local Institution - 0015
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0039
    Durham, North Carolina 27705, United States
  • Local Institution - 0019
    Cincinnati, Ohio 45229, United States
  • Local Institution - 0001
    Cleveland, Ohio 44195-0001, United States
  • Local Institution - 0029
    Columbus, Ohio 43205, United States
  • Local Institution - 0030
    Philadelphia, Pennsylvania 19104-4319, United States
  • Local Institution - 0005
    Pittsburgh, Pennsylvania 15224-1334, United States
  • Local Institution - 0034
    Memphis, Tennessee 38105, United States
  • Local Institution - 0045
    Austin, Texas 78712, United States
  • Local Institution - 0054
    Houston, Texas 77030, United States
  • Local Institution - 0003
    Salt Lake City, Utah 84113-1103, United States
  • Local Institution - 0012
    Charlottesville, Virginia 22908-0816, United States
  • Local Institution - 0020
    Sydney, New South Wales 2145, Australia
  • Local Institution - 0042
    Clayton, Victoria 3168, Australia
  • Local Institution - 0041
    Edmonton, Alberta T6G 2R7, Canada
  • Local Institution - 0046
    Toronto, Ontario M5G 1X8, Canada
  • Local Institution - 0022
    Paris, 75015, France
  • Local Institution - 0026
    Pessac, 33604, France
  • Local Institution - 0006
    Munich, Bavaria 80636, Germany
  • Local Institution - 0018
    Berlin, State of Berlin 13353, Germany
  • Local Institution - 0047
    Dublin 12, D12 N512, D12 N512, Ireland
  • Local Institution - 0016
    Florence, FI 50100, Italy
  • Local Institution - 0051
    Genova, GE 16147, Italy
  • Local Institution - 0027
    Naples, 80131, Italy
  • Local Institution - 0014
    Barcelona, B 8950, Spain
  • Local Institution - 0025
    Madrid, 28046, Spain
  • Local Institution - 0049
    Belfast, BFS BT12 6BA, United Kingdom
  • Local Institution - 0007
    London, WC1N 3JH, United Kingdom
08

References and documents

Publications

  • Rossano JW, Canter C, Wolf CM, Papez A, Gambra M, Bryant RM, Alejos J, McCulloch M, Sarquella Brugada G, Bock MJ, Jeewa A, Pearce FB, Desai MY, Favatella N, Javidialsaadi A, Phung V, Rano T, Zhu L, Dyme JL, Mital S; SCOUT-HCM Investigators. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2026 Jul 23;395(4):362-373. doi: 10.1056/NEJMoa2601103. Epub 2026 Mar 29. PubMed 41910394 ↗
  • Rossano J, Canter C, Wolf C, Favatella N, Lockman J, Puli S, Javidialsaadi A, Dyme J, Crevar C, Mital S. Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial. Am Heart J. 2026 Feb;292:107283. doi: 10.1016/j.ahj.2025.107283. Epub 2025 Sep 30. PubMed 41038603 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Nov 2025, 19 months.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 12, 2024
StartActual
Apr 17, 2024
Primary completionActual
Nov 25, 2025
CompletionEst.
Mar 28, 2031
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06253221
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Apr 17, 2024
Primary completion
Nov 25, 2025
Completion
Mar 28, 2031 (estimated)
Last update
Dec 19, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion